Accelerated Assessment of Comirnaty in Young People Commences
The European Medicines Agency has announced the commencement of an evaluation for the extension of use of Comirnaty, Pfizer/BioNTech’s COVID-19 vaccine, to include young people aged 12 to 15 years.
The European Medicines Agency has announced the commencement of an evaluation for the extension of use of Comirnaty, Pfizer/BioNTech’s COVID-19 vaccine, to include young people aged 12 to 15 years.
In a May 3, 2021 press release, the agency revealed that its Committee for Medicinal Products for Human Use (CHMP) will perform an accelerated assessment of data submitted by the company that markets Comirnaty. The data includes results from a large ongoing clinical study that involves adolescents from 12 years of age.
Any decision made by CHMP will be submitted to the European Commission, which will issue a final legally binding decision for the European Union. EMA will provide further information on the evaluation as it becomes available, which is expected to be in June should no additional information be required.
Source: EMA
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
